Mastodon

Bacteriophage klebsiella pneumoniae purified (Solution) Instructions for Use

Marketing Authorization Holder

Microgen NPO, JSC (Russia)

ATC Code

V03A (Other therapeutic agents)

Dosage Form

Bottle OTC Icon Bacteriophage klebsiella pneumoniae purified Oral, topical and external solution 20 ml: bottle 4 pcs.

Dosage Form, Packaging, and Composition

Solution for oral, topical and external use is transparent, yellow of varying intensity, a greenish tint is allowed.

1 fl.
Sterile purified filtrate of phagolysate of Klebsiella pneumoniae 10 ml

Excipients: 8-hydroxyquinoline sulfate monohydrate 0.0001 g/ml

10 ml – glass bottles (4) – cardboard packs.
10 ml – glass bottles (10) – cardboard packs.
10 ml – glass bottles (4) – contour cell packs (1) – cardboard packs.

Solution for oral, topical and external use is transparent, yellow of varying intensity, a greenish tint is allowed.

1 fl.
Sterile purified filtrate of phagolysate of Klebsiella pneumoniae 20 ml

Excipients: 8-hydroxyquinoline sulfate monohydrate 0.0001 g/ml

20 ml – glass bottles (4) – cardboard packs.
20 ml – glass bottles (10) – cardboard packs.
20 ml – glass bottles (4) – contour cell packs (1) – cardboard packs.

Clinical-Pharmacological Group

Immunobiological drug – bacteriophage

Pharmacotherapeutic Group

MIBP-bacteriophage

Pharmacological Action

The drug causes specific lysis of Klebsiella pneumoniae bacteria.

Indications

Treatment and prevention of diseases caused by Klebsiella pneumoniae bacteria as part of complex therapy

  • Diseases of the gastrointestinal tract (gastroenterocolitis, cholecystitis, pancreatitis, intestinal dysbiosis);
  • Inflammatory diseases of newborns and young children (gastroenterocolitis, intestinal dysbiosis, omphalitis, pemphigus, pyoderma, septicemia and septicopyemia of various localization);
  • Surgical infections (wound suppuration, purulent skin lesions, burns, peritonitis, pleurisy, mastitis, osteomyelitis, abscess);
  • Urogenital infections (cystitis, pyelonephritis, urethritis, endometritis, vulvitis, bartholinitis, colpitis, salpingoophoritis);
  • Purulent-inflammatory diseases of the ear, throat, nose, sinuses, oral cavity, pharynx, larynx, bronchi, lungs and pleura (otitis, tonsillitis, pharyngitis, laryngitis, stomatitis, periodontitis, sinusitis, frontal sinusitis, bronchitis, pneumonia, pleurisy);
  • Post-traumatic conjunctivitis, keratoconjunctivitis, purulent corneal ulcer and iridocyclitis;
  • Prevention of nosocomial infections caused by klebsiella.

An important condition for effective phage therapy is the preliminary determination of the phage sensitivity of the pathogen.

ICD codes

ICD-10 code Indication
B96.1 Klebsiella pneumoniae [K. pneumoniae] as the cause of diseases classified in other chapters
H10.2 Other acute conjunctivitis
H10.4 Chronic conjunctivitis
H16.0 Corneal ulcer
H20.0 Acute and subacute iridocyclitis (anterior uveitis)
H20.1 Chronic iridocyclitis
H66 Suppurative and unspecified otitis media
J01 Acute sinusitis
J02 Acute pharyngitis
J03 Acute tonsillitis
J04 Acute laryngitis and tracheitis
J15 Bacterial pneumonia, not elsewhere classified
J20 Acute bronchitis
J31.0 Chronic rhinitis (including ozaena, atrophic and hypertrophic rhinitis)
J31.2 Chronic pharyngitis
J32 Chronic sinusitis
J35.0 Chronic tonsillitis
J37 Chronic laryngitis and laryngotracheitis
J42 Unspecified chronic bronchitis
J85 Abscess of lung and mediastinum
J86 Pyothorax (pleural empyema)
K05 Gingivitis and periodontal diseases
K12 Stomatitis and related lesions
K29 Gastritis and duodenitis
K52.9 Noninfective gastroenteritis and colitis, unspecified
K63.8 Other specified diseases of intestine
K65.0 Acute peritonitis (including abscess)
K81.0 Acute cholecystitis
K81.1 Chronic cholecystitis
K85 Acute pancreatitis
K86.1 Other chronic pancreatitis
L00 Staphylococcal scalded skin syndrome
L01 Impetigo
L02 Cutaneous abscess, furuncle and carbuncle
L03 Cellulitis
L08.0 Pyoderma
M86 Osteomyelitis
N10 Acute tubulointerstitial nephritis (acute pyelonephritis)
N11 Chronic tubulointerstitial nephritis (chronic pyelonephritis)
N30 Cystitis
N34 Urethritis and urethral syndrome
N61 Inflammatory diseases of the breast
N70 Salpingitis and oophoritis
N71 Inflammatory disease of uterus, excluding cervix (including endometritis, myometritis, metritis, pyometra, uterine abscess)
N72 Inflammatory disease of cervix uteri (including cervicitis, endocervicitis, exocervicitis)
N73.5 Unspecified female pelvic peritonitis
N75 Diseases of Bartholin's gland
N76 Other inflammatory diseases of vagina and vulva
O91 Infections of the breast associated with childbirth
P36 Bacterial sepsis of newborn
P38 Omphalitis of newborn with or without mild hemorrhage
P39.4 Neonatal skin infection
P39.8 Other specified infections specific to the perinatal period
P78 Other disorders of the digestive system in the perinatal period
T30 Burns and corrosions of unspecified body region
T79.3 Posttraumatic wound infection, not elsewhere classified
Z29.8 Other specified prophylactic measures
ICD-11 code Indication
1B70.1 Streptococcal cellulitis of the skin
1B70.2 Staphylococcal cellulitis of the skin
1B70.Z Bacterial cellulitis or lymphangitis caused by unspecified bacterium
1B72.0 Bullous impetigo
1B72.1 Nonbullous impetigo
1B72.Z Impetigo, unspecified
1B75.0 Furuncle
1B75.1 Carbuncle
1B75.2 Furunculosis
1B75.3 Pyogenic skin abscess
9A60.Z Conjunctivitis, unspecified
9A76 Corneal ulcer
9A96.Y Other specified anterior uveitis
9A96.Z Anterior uveitis, unspecified
AA9Z Unspecified suppurative otitis media
CA01 Acute rhinosinusitis
CA02.Z Acute pharyngitis, unspecified
CA03.Z Acute tonsillitis, unspecified
CA05 Acute laryngitis or tracheitis
CA09.0 Chronic rhinitis
CA09.2 Chronic pharyngitis
CA0A.Z Chronic rhinosinusitis, unspecified
CA0F.Y Other specified chronic diseases of the palatine tonsils and adenoids
CA0G Chronic laryngitis or laryngotracheitis
CA20.1Z Chronic bronchitis, unspecified
CA40.0Z Bacterial pneumonia, unspecified
CA42.Z Acute bronchitis, unspecified
CA43.Z Abscess of lung or mediastinum, unspecified
CA44 Pyothorax
DA01.Z Diseases of the oral mucosa, unspecified
DA0B.Z Gingival diseases, unspecified
DA0C.Z Periodontal diseases, unspecified
DA0Z Diseases or disorders of the orofacial complex, unspecified
DA42.Z Gastritis, unspecified
DA51.Z Duodenitis, unspecified
DA7Z Diseases of stomach or duodenum, unspecified
DA90.0 Syndromic diarrhea
DA92.1 Pneumatosis intestinalis of the small intestine
DA98.Z Polyps of small intestine, unspecified
DB31.1 Pneumatosis of the colon
DB36.Z Certain infections of the colon, unspecified
DC12.0Z Acute cholecystitis, unspecified
DC12.1 Chronic cholecystitis
DC31.Z Acute pancreatitis, unspecified
DC32.0 Calcific pancreatitis
DC32.1 Paraduodenal pancreatitis
DC32.2 Hereditary chronic pancreatitis
DC32.4 Chronic idiopathic pancreatitis
DC32.5 Tropical pancreatitis
DC32.Z Chronic pancreatitis, unspecified
DC33 Autoimmune pancreatitis
DC50.0 Primary peritonitis
DC50.2 Peritoneal abscess
DC50.Z Peritonitis, unspecified
DE2Z Diseases of the digestive system, unspecified
EA50.2 Staphylococcal scalded skin syndrome
EB21 Pyoderma gangrenosum
EH1Z Neonatal infection of the skin, unspecified
FB84.Z Osteomyelitis or osteitis, unspecified
GA00 Vulvitis
GA01.Z Inflammatory diseases of uterus, except cervix, unspecified
GA02.Z Unspecified vaginitis
GA03.Z Diseases of Bartholin's gland, unspecified
GA05.2 Unspecified pelvic peritonitis in women
GA07.Z Salpingitis and oophoritis, unspecified
GA0Z Inflammatory diseases of female genital tract, unspecified
GB21.Z Inflammatory diseases of the breast, unspecified
GB50 Acute tubulo-interstitial nephritis
GB51 Acute pyelonephritis
GB55.Z Chronic tubulo-interstitial nephritis, unspecified
GB5Z Renal tubulo-interstitial diseases, unspecified
GC00.Z Cystitis, unspecified
GC02.Z Urethritis and urethral syndrome, unspecified
JB45.Z Infections of the breast associated with childbirth, unspecified
KA60 Fetal or neonatal sepsis
KA65.1 Omphalitis of newborn
KA6Z Infections of fetus or newborn, unspecified
KB80 Gastro-esophageal reflux disease in newborns
KB81.0 Eosinophilic esophagitis in newborns
KB8Z Digestive system disorders of fetus or newborn, unspecified
NE11 Burn of unspecified body region
NF0A.3 Posttraumatic wound infection, not elsewhere classified
QC05.Z Prophylactic measures, unspecified
XN741 Klebsiella pneumoniae
GA0Z Inflammatory diseases of female genital tract, unspecified
XA5WW1 Cervix uteri

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

The drug is used for oral administration (by mouth), in the form of enemas, applications, irrigations, introduction into wound cavities, vagina, uterus, nose, sinuses, as well as into drained cavities: abscesses, abdominal, pleural, bladder, renal pelvis.

The drug is taken orally on an empty stomach 0.5-1 hour before meals.

Recommended doses of the drug

Patient age Dose per administration for various methods of drug administration
Orally (ml) In enema (ml)
0-6 months 5 10
6-12 months 10 20
1 to 3 years 15 20-30
3 to 8 years 20 30-40
8 years and older 20-30 40-50

Treatment of purulent-inflammatory diseases with localized lesions should be carried out simultaneously both locally and by taking the drug orally.

In case of treatment of a purulent focus cavity with chemical antiseptics before using the bacteriophage, it should be washed with a sterile 0.9% sodium chloride solution.

For treatment of tonsillitis, pharyngitis, laryngitis, the drug is used for rinsing the mouth and throat 3 times a day, 10-20 ml, course of treatment 7-10 days.

For treatment of bronchitis, pneumonia, the drug is taken orally 3 times a day, 10-20 ml, and also used in the form of inhalations (without heating and using ultrasound), course of treatment 15-20 days.

For treatment of otitis, the drug is used for washing and introduction into the middle ear cavity, 2-5 ml 1-3 times a day. Course of treatment 7-15 days.

For treatment of sinus inflammation, the drug is used for washing the nasal cavity, nasopharynx and sinuses in a dose of 5-10 ml and introduction into the sinuses 2-3 ml. The procedure is repeated once daily for 7-10 days. In addition, the drug is introduced into the nasal cavity in the form of turundas soaked in bacteriophage, alternately into each nasal passage and left for 0.5-1 hour. The procedure is repeated 3 times a day, course of treatment 7-15 days.

For treatment of stomatitis and chronic generalized periodontitis, the drug is used in the form of mouth rinses 3-4 times a day in a dose of 10-20 ml, as well as by introducing turundas soaked in klebsiella bacteriophage into periodontal pockets for 5-10 minutes, course of treatment 7-10 days.

For conjunctivitis and keratoconjunctivitis, the drug is applied 2-3 drops 4-5 times a day, course of treatment 5-7 days; for purulent corneal ulcer – 4-5 drops a day for 7-10 days, for purulent iridocyclitis – 6-8 drops every 3 hours in combination with oral administration in therapeutic dosages for 7-10 days.

For abscesses after opening and removal of purulent contents, the drug is introduced in an amount less than the volume of removed pus once daily, course of treatment 7-10 days.

For peritonitis and pleurisy, the drug is introduced into drained cavities – abdominal and pleural through drainage tubes once daily 20-70 ml, course of treatment 10-15 days.

For osteomyelitis, the drug is introduced into the wound cavity through turundas, drainages in an amount of 10-30 ml once daily, course of treatment 15-20 days.

For treatment of wound suppurations, the drug is used in the form of irrigation, applications, dressings, introduction into drainage in a dose of 5-50 ml depending on the lesion focus at least once a day, course of treatment 10-15 days.

For treatment of purulent-inflammatory gynecological diseases (wound suppurations, endometritis, vulvitis, bartholinitis, colpitis, salpingoophoritis), the drug is used for irrigations, applications, introduced into wound cavities, vagina, uterus 5-20 ml once a day for 7-10 days.

For cystitis, pyelonephritis, urethritis, the drug is taken orally in a therapeutic dose 3 times a day 1 hour before meals for 10-20 days. In the case when the bladder cavity or renal pelvis is drained, the drug is administered through a cystostomy or nephrostomy 1-3 times a day, 20-50 ml into the bladder and 5-7 ml into the renal pelvis, course of treatment 7-15 days.

For gastroenterocolitis, pancreatitis, cholecystitis, as well as intestinal dysbiosis, the bacteriophage is taken orally in age-specific dosages 3 times a day 1 hour before meals for 7-15 days (according to clinical indications). In case of uncontrollable vomiting, the drug is used in the form of high enemas 2-3 times a day, 20-40 ml. For intestinal dysbiosis, the drug can be used with normoflora preparations.

For prevention of nosocomial surgical infections, the drug is used for treatment of postoperative and freshly infected wounds in a dose of 5 -50 ml depending on the lesion focus once daily for 5-7 days.

Use of the drug in children under 1 year of age (including premature infants).

For gastroenterocolitis, pneumonia and sepsis of newborns, the drug is applied orally 2-3 times a day, 3-5 ml 30 minutes before feeding. In cases of uncontrollable vomiting, the drug is used in the form of high enemas (through a gas outlet tube or catheter) once daily in a dose of 5-10 ml. A combination of rectal (in the form of high enemas) and oral administration of the drug is possible. Course of treatment 7-15 days (according to clinical indications). In case of recurrent disease, repeated courses of treatment are possible.

For the purpose of preventing the occurrence of nosocomial infection in newborn children, the bacteriophage is used according to epidemic indications orally, 3-5 ml 3 times a day 30 minutes before feeding for the entire period of stay in the hospital.

For treatment of omphalitis, pyoderma, infected wounds, the bacteriophage is used in the form of applications, 5-10 ml 2-3 times a day (a gauze napkin is moistened with bacteriophage and applied to the umbilical wound or affected area of the skin) for 7-15 days.

The use of the drug does not exclude the use of other antibacterial and anti-inflammatory drugs.

Adverse Reactions

Not established.

Contraindications

  • Hypersensitivity to the components of the drug.

Use in Pregnancy and Lactation

The use of this drug during pregnancy and breastfeeding is possible in the presence of infections caused by phage-sensitive strains of klebsiella (as recommended by a doctor).

Pediatric Use

Use in children is possible according to indications.

Special Precautions

Precautions for use

Do not use the preparation if it becomes cloudy!

Due to the content of the nutrient medium in the preparation, in which bacteria from the environment can develop, causing cloudiness of the preparation, the following rules must be observed when opening the vial

  • Wash hands thoroughly;
  • Treat the cap with an alcohol-containing solution;
  • Remove the cap without opening the stopper;
  • Do not place the stopper with the inner surface on a table or other objects;
  • Do not leave the vial open;
  • Store the opened vial only in the refrigerator.

When using small doses (2-8 drops), the preparation must be drawn up with a sterile syringe in a volume of 0.5-1 ml.

The preparation from an opened vial, if storage conditions and the above rules are observed and there is no cloudiness, can be used throughout the entire shelf life.

Effect on ability to drive vehicles and machinery

Absent.

Overdose

Not established.

Drug Interactions

The use of the preparation is possible in combination with other medicines, including antibiotics.

Storage Conditions

The preparation should be stored in accordance with SP 3.3.2.1248-03 in a dry place, protected from light and out of the reach of children, at a temperature between 2°C and 8°C (46.4°F).

Shelf Life

Shelf life – 2 years.

Dispensing Status

Without a prescription.

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

TABLE OF CONTENTS